Literature DB >> 17523019

Prediction of anti-tumour effect of thermochemotherapy with in vitro thermochemosensitivity testing for non-small cell lung cancer.

T Abiko1, M Kawamura, Y Izumi, T Oyama, Y Saito, K Kobayashi.   

Abstract

PURPOSE: We investigated whether it is possible to predict the antitumour effects of thermochemotherapy from the results of anticancer agent sensitivity testing.
MATERIALS AND METHODS: We produced a nude mouse cancer model using 4 lung cancer cell lines. Animals were divided into 4 groups: Thermotherapy (HT group), chemotherapy (CT group), thermochemotherapy (HT+CT group), and no therapy (NT group). Comparison of in vivo and in vitro effects were performed using cisplatin (CDDP), doxorubicin (ADR) and vinorelbine (NVB). In vivo thermotherapy was performed using the Thermotron RF IV, and radiofrequency (RF) capacitative hyperthermia device that induces a localised temperature of 42.0 degrees C for 45 min. The collagen gel embedded culture drug sensitivity test (CD-DST) was used for in vitro chemosensitivity analysis of the anticancer agents. In vitro thermochemotherapy was performed using a modified CD-DST method, with the incubator set at 42.0 degrees for the first hour of the 24 hours drug exposure period.
RESULTS: A good correlation was seen between in vivo and in vitro treated/control ratios (T/C%) in the HT group (R = 0.91, p = 0.09). Good correlations were also seen between in vivo and in vitro T/C in all cell lines in the CT group (R = 0.759, p = 0.09) and the HT+CT group (R = 0.65, p = 0.02). True positive rate was 87.5% (7/8), and true negative rate was 100% (4/4). Sensitivity, specificity and accuracy were 100% (7/7), 80% (4/5), and 91.7% (11/12) respectively.
CONCLUSION: A modified CD-DST using an exposure temperature of 42 degrees C can be used to predict the antitumour effect of thermochemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523019     DOI: 10.1080/02656730701286333

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  4 in total

1.  Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 in treating patients of non-small cell lung cancer at peri-operational stage.

Authors:  Qing-cong Du; Kui-zhong Yang; Xue-fei Sun
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

2.  Optimized treatment with RF thermotherapy and immunotherapy combined with CyberKnife for advanced high-risk tumors: A clinical trial report.

Authors:  Zhigao Jiang; Qinwen Wang; Guiqing Yang; Xiaoxu Liu; Dongning Sun; Shanshan Wang; Yang Li; Yishan Wang
Journal:  Biomed Rep       Date:  2014-01-10

3.  Clinical efficacy of CyberKnife combined with chemotherapy and hyperthermia for advanced non-small cell lung cancer.

Authors:  Yuan-Yuan Wang; Si-Xiang Lin; Gui-Qing Yang; Han-Chen Liu; Dong-Ning Sun; Yi-Shan Wang
Journal:  Mol Clin Oncol       Date:  2013-03-19

4.  Aquaporin 1 promotes sensitivity of anthracycline chemotherapy in breast cancer by inhibiting β-catenin degradation to enhance TopoIIα activity.

Authors:  Wei Chong; Huikun Zhang; Zhifang Guo; Limin Yang; Ying Shao; Xiaoli Liu; Yawen Zhao; Zhe Wang; Ming Zhang; Caixia Guo; Li Fu; Yongjie Ma; Feng Gu
Journal:  Cell Death Differ       Date:  2020-08-19       Impact factor: 15.828

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.